The Claim

In adults with overweight or obesity (BMI ≥27 kg/m²) and at least one comorbidity, weekly subcutaneous administration of pemvidutide at 2.4 mg for 48 weeks causes a mean weight loss of 15.6% compared to 2.2% with placebo, with 51.8% of participants achieving at least 15% weight loss and 48% no longer meeting obesity criteria by trial end.

Source: 262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
69score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with overweight or obesity and at least one related health condition, a weekly injection of pemvidutide for 48 weeks resulted in an average weight loss of 15.6%, compared to 2.2% with a placebo. Over half of those receiving the treatment lost at least 15% of their body weight, and nearly half no longer met the clinical definition of obesity.

See the scientific wording

In adults with overweight or obesity (BMI ≥27 kg/m²) and at least one comorbidity, weekly subcutaneous administration of pemvidutide at 2.4 mg for 48 weeks causes a mean weight loss of 15.6% compared to 2.2% with placebo, with 51.8% of participants achieving at least 15% weight loss and 48% no longer meeting obesity criteria by trial end.

Why this might work

This medicine binds to two special receptors in the body: one that tells the brain you're full, and another that makes the liver burn more fat and energy. Together, this makes you eat less and burn more calories, so you lose weight.

Supported mechanismbased on 1 study

What the research says

1 study

  1. Study: 262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

    This study tested a weekly shot called pemvidutide in people with extra weight and health problems, and it worked: on average, people lost 15.6% of their body weight—much more than those who got a placebo—and almost half of them no longer qualified as obese by the end.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.